[Antithrombotic prophylaxis of the complications of arteriosclerosis obliterans]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Vascular Biology

Background:

• Atherosclerosis, including cerebral, coronary, and peripheral artery disease, poses a significant global health burden.
• Antithrombolytic therapies are crucial for managing atherosclerotic conditions and preventing thrombotic events.
• Optimizing combination therapies remains a key area of research to improve patient outcomes.

Purpose of the Study:

• To evaluate the clinical efficacy of combined antithrombolytic drug regimens.
• To assess the impact of specific drug combinations on patient survival and vascular catastrophe rates.
• To provide evidence-based recommendations for managing patients with complex atherosclerotic diseases.

Main Methods:

• A large cohort of patients diagnosed with cerebral, coronary, and obliterating atherosclerosis was studied.
• The study involved the regular administration of acetylsalicylic acid in combination with coumarin derivatives.
• Clinical outcomes, including mortality and incidence of vascular events, were monitored.

Main Results:

• Regular administration of acetylsalicylic acid combined with coumarin derivatives demonstrated a significant prolongation of patient life.
• This combination therapy was associated with a notable decrease in the number of vascular catastrophes.
• The findings highlight the synergistic effect of the studied drug combination.

Conclusions:

• Combined therapy with acetylsalicylic acid and coumarin derivatives is effective in improving long-term survival for cardiovascular disease patients.
• This regimen is a valuable strategy for reducing the risk of thrombotic events in patients with atherosclerosis.
• The study supports the use of this antithrombolytic combination for managing complex vascular diseases.